Cite
HARVARD Citation
Fox, E. et al. (2018). Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Multiple sclerosis. pp. 1862-1870. [Online].